Medical condition
Hepatocellular Carcinoma
Hepatocellular Carcinoma is a medical condition tracked by NovaPharmaNews across 11 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- cabozantinib (CABOMETYX) Antineoplastic and immunomodulating agents (L01)
- atezolizumab (TECENTRIQ) Antineoplastic and immunomodulating agents (L01)
- ipilimumab (YERVOY) Antineoplastic and immunomodulating agents (L01)
- nivolumab (OPDIVO) Antineoplastic and immunomodulating agents (L01)
- ramucirumab (CYRAMZA) Antineoplastic and immunomodulating agents (L01)
- regorafenib (STIVARGA) Antineoplastic and immunomodulating agents (L01)
- durvalumab (IMFINZI) Antineoplastic and immunomodulating agents (L01)
- lenvatinib (LENVIMA) Antineoplastic and immunomodulating agents (L01)
- mangafodipir (TESLASCAN) Various (V08)
- sorafenib (NEXAVAR) Antineoplastic and immunomodulating agents (L01)
- tremelimumab (IMJUDO) Antineoplastic and immunomodulating agents (L01)
Clinical pipeline & programs
Explore Oncology drug development programs tracked across clinical phases.